Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Trulicity ® (dulaglutide)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Trulicity Summary of Product Characteristics (SmPC)
How should other medications be administered with Trulicity® (dulaglutide)?
Consider reducing insulin/insulin secretagogue dose when initiating Trulicity (dulaglutide). Dulaglutide may reduce absorption of orally co-administered drugs.
Potential for Dulaglutide to Influence the Pharmacokinetics of Other Drugs
Dulaglutide slows gastric emptying and, as a result, may reduce the extent and rate of absorption of orally coadministered medications.1
In clinical pharmacology studies, treatment with dulaglutide did not affect, to any clinically relevant degree, the absorption of coadministered oral medications that included
lisinopril
warfarin
metoprolol
digoxin
norelgestromin
ethinylestradiol
atorvastatin
metformin
paracetamol, and
sitagliptin.1
No dose adjustment is recommended for any of these evaluated coadministered medications.1
Concomitant Use With an Insulin Secretagogue or With Insulin
To reduce the risk of hypoglycemia when initiating dulaglutide treatment, consider reducing the dosage of concomitantly administered
insulin secretagogues, such as sulfonylureas, or
insulin.1
1. Trulicity [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
Date of Last Review: July 13, 2020
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com
Available Mon - Fri, 10am - 4pm, excluding Bank Holidays